The Role of Ninjurin-1 During Systemic Inflammation

NCT ID: NCT02079597

Last Updated: 2014-09-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-02-28

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

* With the underlying study the investigators address the question if Ninjurin-1 (Ninj1) expression is altered in patients with systemic inflammatory response syndrome (SIRS) in comparison to healthy volunteers.
* The adhesion molecule Ninj1 is induced following nerve injury where it contributes to nerve generation. Besides it is described to facilitate leukocyte migration especially in the nervous system.
* The investigators hypothesize that Ninj1 expression is increased in SIRS patients, which will fortify its impact during inflammation and the transferability from bench to bedside.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ninj1 Expression SIRS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy

Healthy individuals no infection

No interventions assigned to this group

SIRS

SIRS patients no included in an interventional study no peroperative infection

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age \> 18 years
* cardiac surgery patients

Exclusion Criteria

* included in an interventional study
* Preoperative Infection (e.g. Endocarditis)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Dr. Patrick Meybohm, M.D.

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr. Patrick Meybohm, M.D.

PD Dr. Patrick Meybohm, M.D.

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Patrick Meybohm, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Anesthesiology, University Hospital Frankfurt

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Anesthesiology, University Hospital Frankfurt

Frankfurt am Main, Hesse, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NINJ1-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

AUTOANTIBODIES AND SYSTEMIC SCLEROSIS
NCT06502678 NOT_YET_RECRUITING
Biomarkers of Cancer-Associated Myositis
NCT06808672 ACTIVE_NOT_RECRUITING
CSL Behring Sclero XIII
NCT02551042 UNKNOWN PHASE2
Research in Skin Inflammation
NCT00026741 COMPLETED